Ocugen Inc (OCGN)

Overview News Price History Option Chain Discussions Forecast Stock Split

Ocugen Inc stock is currently priced at $1.32, with a 24-hour trading volume of 6.49M. It has seen a +0.00% increased in the last 24 hours and a +20.00% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.37 pivot point. If it approaches the $1.22 support level, significant changes may occur.

Ocugen Inc Stock (OCGN) Financials Data

Ocugen Inc (OCGN) Net Income 2024

OCGN net income (TTM) was -$75.52 million for the quarter ending September 30, 2023, a -2.07% decrease year-over-year.

Ocugen Inc (OCGN) Cash Flow 2024

OCGN recorded a free cash flow (TTM) of -$77.44 million for the quarter ending September 30, 2023, a -32.17% decrease year-over-year.

Ocugen Inc (OCGN) Earnings per Share 2024

OCGN earnings per share (TTM) was -$0.33 for the quarter ending September 30, 2023, a +5.71% growth year-over-year.

Ocugen Inc Stock (OCGN) Latest News

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

GlobeNewswire Inc.

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

GlobeNewswire Inc.

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

GlobeNewswire Inc.

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study

Zacks Investment Research

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

GlobeNewswire Inc.

Here’s 3 Strategies for Options Trading With Penny Stocks

PennyStocks

Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.

Upgrade	Chardan Capital Markets: Neutral → Buy	Mar-01-23
Initiated	Mizuho: Buy	Aug-23-22
Resumed	ROTH Capital: Buy	Jun-15-22
Initiated	Cantor Fitzgerald: Overweight	Jun-02-22
Initiated	Noble Capital Markets: Outperform	Jul-26-21
Downgrade	ROTH Capital: Buy → Neutral	Jun-11-21
Downgrade	Cantor Fitzgerald: Overweight → Neutral	May-07-21
Downgrade	Chardan Capital Markets: Buy → Neutral	Feb-09-21
Upgrade	H.C. Wainwright: Neutral → Buy	Feb-04-21